Shorter infusions for fabry disease: a step toward less burden

NCT ID NCT06019728

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 18 times

Summary

This study tested whether people with Fabry disease can safely receive their Fabrazyme infusions faster and with less fluid. Eight participants who had been on Fabrazyme for at least 3 months without reactions took part. The goal was to reduce infusion time while keeping the treatment safe and tolerable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FABRY'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Emory University School of Medicine Site Number : 1005

    Atlanta, Georgia, 30322-1007, United States

  • Infusion Associates Site Number : 1001

    Grand Rapids, Michigan, 49525, United States

  • Lysosomal and Rare Disorders Research and Treatment Center, Inc Site Number : 1002

    Fairfax, Virginia, 22030, United States

  • Metropolitan Hospital Center Site Number : 1004

    New York, New York, 10021, United States

  • UCLA Medical Center Site Number : 1003

    Santa Monica, California, 90404, United States

Conditions

Explore the condition pages connected to this study.